174 related articles for article (PubMed ID: 20204580)
1. Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.
Achenbach CJ; Scarsi KK; Murphy RL
Adv Ther; 2010 Jan; 27(1):1-16. PubMed ID: 20204580
[TBL] [Abstract][Full Text] [Related]
2. Abacavir and lamivudine combination.
Somboonwit C; Kurtyka D; Velez AP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
[TBL] [Abstract][Full Text] [Related]
3. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
4. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.
Dando TM; Scott LJ
Drugs; 2005; 65(2):285-302. PubMed ID: 15631548
[TBL] [Abstract][Full Text] [Related]
5. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Cohen CJ; Kubota M; Brachman PS; Harley WB; Schneider S; Williams VC; Sutherland-Phillips DH; Lim ML; Balu RB; Shaefer MS;
Pharmacotherapy; 2008 Mar; 28(3):314-22. PubMed ID: 18294111
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine for the treatment of HIV.
Kumar PN; Patel P
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):105-14. PubMed ID: 20001611
[TBL] [Abstract][Full Text] [Related]
7. Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Rizzardini G; Zucchi P
Expert Opin Pharmacother; 2011 Sep; 12(13):2129-38. PubMed ID: 21787242
[TBL] [Abstract][Full Text] [Related]
8. [New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():66-8. PubMed ID: 16385881
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Bollen P; Reiss P; Schapiro J; Burger D
Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
[TBL] [Abstract][Full Text] [Related]
12. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
Anderson AM; Bartlett JA
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):871-83. PubMed ID: 16307500
[TBL] [Abstract][Full Text] [Related]
13. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
[TBL] [Abstract][Full Text] [Related]
14. Abacavir: new preparation. Risks limit the value.
Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
[TBL] [Abstract][Full Text] [Related]
15. Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
Dorjee K; Desai M; Choden T; Baxi SM; Hubbard AE; Reingold AL
AIDS Res Ther; 2021 Sep; 18(1):57. PubMed ID: 34488812
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir, abacavir and lamivudine as HIV therapy.
Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
[TBL] [Abstract][Full Text] [Related]
17. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
18. Abacavir sulfate, lamivudine, and zidovudine (Trizivir).
Porche D
J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917
[TBL] [Abstract][Full Text] [Related]
19. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
[TBL] [Abstract][Full Text] [Related]
20. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]